Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.
Bausch + Lomb Corporation is a global eye health company that develops, manufactures, and markets products for vision correction, eye care, and surgical treatment. The company operates through three business segments: Vision Care, Pharmaceuticals, and Surgical, serving markets in nearly 100 countries worldwide.
The Vision Care segment produces contact lenses across all wearing modalities, including daily disposable and frequently replaced lenses, along with lens care products, over-the-counter eye drops, and eye vitamins. The Pharmaceuticals segment offers prescription medications for conditions such as glaucoma, dry eye disease, eye inflammation, and retinal diseases. The Surgical segment provides intraocular lenses, phacoemulsification equipment, and surgical instruments used in cataract and retinal procedures.
With approximately 400 products in its portfolio, Bausch + Lomb serves eye care professionals, healthcare providers, and consumers through well-known brands including Biotrue, PreserVision, Lumify, XIIDRA, Vyzulta, Lotemax, and Ocuvite. The company maintains global research, development, manufacturing, and commercial operations to support its position in the international eye care products market.
News and developments related to Bausch + Lomb may include product launches, regulatory approvals for new medications or medical devices, clinical trial results, strategic partnerships, acquisitions of complementary businesses or technologies, manufacturing expansions, and updates on the company's financial performance across its three operating segments in various geographic markets.
FAQ
What is the current stock price of Bausch + Lomb Corporation (BLCO)?
What is the market cap of Bausch + Lomb Corporation (BLCO)?
